Longeveron Looks for New Ways After Trial Miss
Longeveron faces big changes after its stem cell treatment for a heart disease did not meet its main goal in a study.
A company named Longeveron is making big news. Their special stem cell treatment helps children with a serious heart problem. This treatment, called Lomecel-B, recently finished a key study. The results came out, and the treatment did not work as hoped.
The study was a Phase 2b trial. It looked at how well Lomecel-B helped children with hypoplastic left heart syndrome (HLHS). HLHS is a rare and serious condition. Children born with it have a part of their heart that is not fully formed. The trial's main goal was not met.
Because of this setback, Longeveron must now make changes. The company will cut costs. It will also look at all possible paths for its future. This includes finding new ways to use its treatments or new ways to run the business. This move ensures the company plans for its next steps.
Source: FierceBiotech
More from Biotech
